Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate

ABSTRACT:

Background

Variable fibrinogen content within cryoprecipitate makes accurate dosing challenging in patients with coagulopathic bleeding, in addition to pathogen transmission risks associated with its administration. Purified and standardized human fibrinogen concentrates (HFCs) represent reliable alternatives. Full cryoprecipitate characterization is required to inform selection of an appropriate fibrinogen source for supplementation therapy.

Methods

Extended biochemical comparison of pooled cryoprecipitate and HFC (Fibryga, Octapharma) was performed using commercially available assays to determine levels of variability in cryoprecipitate and HFC. In addition to standard procoagulant factors, measurements included activities of platelet-derived microparticles (PMPs) and p

SUBMITTER: Stanford S 

PROVIDER: S-EPMC10468048 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature